Joseph Diab1, Terkel Hansen1, Rasmus Goll2,3, Hans Stenlund4, Maria Ahnlund4, Einar Jensen1, Thomas Moritz3, Jon Florholmen2,3, Guro Forsdahl1. 1. Natural Products and Medicinal Chemistry Research Group, Department of Pharmacy Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, Tromsø, Norway. 2. Research Group of Gastroenterology and Nutrition, Department of Clinical Medicine, Faculty of Health Sciences, University of Tromsø-The Arctic University of Norway, Tromsø, Norway. 3. Department of Medical Gastroenterology, University Hospital of North Norway, Tromsø, Norway. 4. Swedish Metabolomics Center, Swedish University of Agricultural Sciences, Umeå, Sweden.
Abstract
BACKGROUND: The onset of ulcerative colitis (UC) is associated with alterations in lipid metabolism and a disruption of the balance between pro- and anti-inflammatory molecules. Only a few studies describe the mucosal lipid biosignatures during active UC. Moreover, the dynamics of lipid metabolism in the remission state is poorly defined. Therefore, this study aims to characterize mucosal lipid profiles in treatment-naïve UC patients and deep remission UC patients compared with healthy subjects. METHODS: Treatment-naïve UC patients (n = 21), UC patients in deep remission (n = 12), and healthy volunteers (n = 14) were recruited. The state of deep remission was defined by histological and immunological remission defined by a normalized TNF-α gene expression. Mucosa biopsies were collected by colonoscopy. Lipid analysis was performed by means of ultra-high performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS-MS). In total, 220 lipids from 11 lipid classes were identified. RESULTS: The relative concentration of 122 and 36 lipids was altered in UC treatment-naïve patients and UC remission patients, respectively, compared with healthy controls. The highest number of significant variations was in the phosphatidylcholine (PC), ceramide (Cer), and sphingomyelin (SM) composition. Multivariate analysis revealed discrimination among the study groups based on the lipid profile. Furthermore, changes in phosphatidylethanolamine(38:3), Cer(d18:1/24:0), and Cer(d18:1/24:2) were most distinctive between the groups. CONCLUSION: This study revealed a discriminant mucosal lipid composition pattern between treatment-naïve UC patients, deep remission UC patients, and healthy controls. We report several distinctive lipids, which might be involved in the inflammatory response in UC, and could reflect the disease state.
BACKGROUND: The onset of ulcerative colitis (UC) is associated with alterations in lipid metabolism and a disruption of the balance between pro- and anti-inflammatory molecules. Only a few studies describe the mucosal lipid biosignatures during active UC. Moreover, the dynamics of lipid metabolism in the remission state is poorly defined. Therefore, this study aims to characterize mucosal lipid profiles in treatment-naïve UC patients and deep remission UC patients compared with healthy subjects. METHODS: Treatment-naïve UC patients (n = 21), UC patients in deep remission (n = 12), and healthy volunteers (n = 14) were recruited. The state of deep remission was defined by histological and immunological remission defined by a normalized TNF-α gene expression. Mucosa biopsies were collected by colonoscopy. Lipid analysis was performed by means of ultra-high performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS-MS). In total, 220 lipids from 11 lipid classes were identified. RESULTS: The relative concentration of 122 and 36 lipids was altered in UC treatment-naïve patients and UC remission patients, respectively, compared with healthy controls. The highest number of significant variations was in the phosphatidylcholine (PC), ceramide (Cer), and sphingomyelin (SM) composition. Multivariate analysis revealed discrimination among the study groups based on the lipid profile. Furthermore, changes in phosphatidylethanolamine(38:3), Cer(d18:1/24:0), and Cer(d18:1/24:2) were most distinctive between the groups. CONCLUSION: This study revealed a discriminant mucosal lipid composition pattern between treatment-naïve UC patients, deep remission UC patients, and healthy controls. We report several distinctive lipids, which might be involved in the inflammatory response in UC, and could reflect the disease state.
Authors: Abdellah Tebani; Anders Gummesson; Wen Zhong; Ina Schuppe Koistinen; Tadepally Lakshmikanth; Lisa M Olsson; Fredrik Boulund; Maja Neiman; Hans Stenlund; Cecilia Hellström; Max J Karlsson; Muhammad Arif; Tea Dodig-Crnković; Adil Mardinoglu; Sunjae Lee; Cheng Zhang; Yang Chen; Axel Olin; Jaromir Mikes; Hanna Danielsson; Kalle von Feilitzen; Per-Anders Jansson; Oskar Angerås; Mikael Huss; Sanela Kjellqvist; Jacob Odeberg; Fredrik Edfors; Valentina Tremaroli; Björn Forsström; Jochen M Schwenk; Peter Nilsson; Thomas Moritz; Fredrik Bäckhed; Lars Engstrand; Petter Brodin; Göran Bergström; Mathias Uhlen; Linn Fagerberg Journal: Nat Commun Date: 2020-09-08 Impact factor: 14.919
Authors: Maeve Long; Alvaro Sanchez-Martinez; Marianna Longo; Fumi Suomi; Hans Stenlund; Annika I Johansson; Homa Ehsan; Veijo T Salo; Lambert Montava-Garriga; Seyedehshima Naddafi; Elina Ikonen; Ian G Ganley; Alexander J Whitworth; Thomas G McWilliams Journal: EMBO J Date: 2022-04-12 Impact factor: 14.012
Authors: Carl Herdenberg; Pascal M Mutie; Ola Billing; Ahmad Abdullah; Rona J Strawbridge; Ingrid Dahlman; Simon Tuck; Camilla Holmlund; Peter Arner; Roger Henriksson; Paul W Franks; Håkan Hedman Journal: Commun Biol Date: 2021-01-19
Authors: Lidiya V Boldyreva; Maryana V Morozova; Snezhanna S Saydakova; Elena N Kozhevnikova Journal: Int J Mol Sci Date: 2021-10-28 Impact factor: 5.923
Authors: Joseph Diab; Terkel Hansen; Rasmus Goll; Hans Stenlund; Einar Jensen; Thomas Moritz; Jon Florholmen; Guro Forsdahl Journal: Metabolites Date: 2019-11-27